comparemela.com

Latest Breaking News On - Nostrand robertl van - Page 1 : comparemela.com

Intra-Cellular Therapies (NASDAQ:ITCI) Price Target Raised to $73 00 at Needham & Company LLC

Intra-Cellular Therapies (NASDAQ:ITCI) Price Target Raised to $73 00 at Needham & Company LLC
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

Intra-Cellular Therapies (NASDAQ:ITCI) PT Raised to $80 00 at UBS Group

Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) had its price objective increased by UBS Group from $74.00 to $80.00 in a report issued on Friday morning, The Fly reports. ITCI has been the topic of several other research reports. Canaccord Genuity Group upped their price objective on shares of Intra-Cellular Therapies from $93.00 to $98.00 and […]

UBS Group Increases Intra-Cellular Therapies (NASDAQ:ITCI) Price Target to $80 00

Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) had its price objective increased by UBS Group from $74.00 to $80.00 in a report published on Friday, The Fly reports. Other research analysts have also issued research reports about the company. Bank of America lifted their price target on Intra-Cellular Therapies from $62.00 to $63.00 and gave the […]

Intra-Cellular Therapies, Inc (NASDAQ:ITCI) Shares Sold by Quantum Private Wealth LLC

Quantum Private Wealth LLC cut its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 4.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,894 shares of the biopharmaceutical company’s stock after selling 765 shares during the period. Quantum […]

Vahanian & Associates Financial Planning Inc Sells 2,460 Shares of Intra-Cellular Therapies, Inc (NASDAQ:ITCI)

Vahanian & Associates Financial Planning Inc. lessened its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) by 13.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 16,132 shares of the biopharmaceutical company’s stock after selling 2,460 shares during […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.